PledPharma AB | Innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments do not exist.

Rights issue

Prospectus

Pipeline

Analyst presentation; acquisition of RTT

Go to the link

Press Releases

Regulatory

November 25, 2020

PledPharma raises SEK 250 million in oversubscribed rights issue and utilized overallotment option

Regulatory

November 23, 2020

Clarification regarding ownership changes in PledPharma

November 18, 2020

FDA grants Rare Pediatric Disease designation to Emcitate®

Latest Report

November 11, 2020

Latest interim report

March 30, 2020

Annual report 2019 (in Swedish)

Latest presentation

October 19, 2020

Swedish Shareholders' Association, Shareholders' day

Calendar and upcoming reports

November 11, 2020

Interim report third quarter 2020

November 9-23, 2020

Subscription period rights issue

November 9-12, 2020

Trading in subscription rights

December 11, 2020

Extra General Meeting

February 17, 2021

Year end report

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com